Zinc-{alpha}2-glycoprotein: a New Biomarker of Breast Cancer?
By: Dubois V, Delort L, Mishellany F, Jarde T, Billard H, Lequeux C, Damour O, Penault-Llorca F, Vasson MP, Caldefie-Chezet F.

Faculté de Pharmacie, Laboratoire SVFp, 28 place Henri-Dunant, B.P. 38, 63000 Clermont-Ferrand, France. virginie.dubois@u-clermont1.fr.
Anticancer Res. 2010 Jul; 30(7):2919-25.

Abstract

Background/aim

Obesity increases the risk of breast cancer. It is established that adipocyte secretions, i.e. adipokines, may play a role in mammary carcinogenesis. We have shown that two major adipokines, leptin and adiponectin, were expressed in mammary adenocarcinoma.

Patients and Methods

Here, we evaluated zinc-alpha2-glycoprotein (ZAG) expression in tumor (n=55) and healthy (n=6) breast tissue by immunohistochemistry and examined whether it was correlated with that of major adipokines, usual tumor biomarkers (sex steroids receptors, i.e. estrogen (ER) and progesterone; Ki-67; cErb2), or apoptosis markers (Bcl2 and Bax).

Results

ZAG expression was detected in ductal carcinoma and normal epithelial adjacent tissue but not in normal tissue of healthy women. In cancer tissue, its expression was correlated positively to leptin receptor and negatively to adiponectin receptor and ER.

Conclusion

These preliminary results suggest both a relationship between ZAG expression and pathways involving adipokines or estrogen and that ZAG may be a potential breast cancer biomarker.

PMID: 20683033 [PubMed - in process] Source: National Library of Medicine.







Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements